A share price of Kymera Therapeutics Inc [KYMR] is currently trading at $86.88, down -7.87%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KYMR shares have gain 35.18% over the last week, with a monthly amount glided 48.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, B. Riley Securities reaffirmed its Buy rating on October 24, 2025, and elevated its price target to $80. On October 21, 2025, Mizuho initiated with an Outperform rating and assigned a price target of $81 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $70 on September 18, 2025. Barclays initiated its recommendation with an Overweight and recommended $60 as its price target on September 17, 2025. RBC Capital Mkts started tracking with an Outperform rating for this stock on September 16, 2025, and assigned it a price target of $70.
Kymera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $19.44 and $103.00. Currently, Wall Street analysts expect the stock to reach $114.21 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $86.88 at the most recent close of the market. An investor can expect a potential return of 31.46% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Trailing Twelve Months sales for Kymera Therapeutics Inc [NASDAQ:KYMR] were 43.73M which represents -26.12% decline. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -7.6%, Pretax Profit Margin comes in at -6.75%, and Net Profit Margin reading is -6.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.33 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 84.22 points at the first support level, and at 81.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 90.32, and for the 2nd resistance point, it is at 93.76.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kymera Therapeutics Inc [NASDAQ:KYMR] is 7.38. Also, the Quick Ratio is 7.38, while the Cash Ratio stands at 1.58. Considering the valuation of this stock, the price to sales ratio is 142.94, the price to book ratio is 6.59.
Transactions by insiders
Recent insider trading involved Albers Jeffrey W., Director, that happened on Dec 08 ’25 when 5000.0 shares were sold. Chief Executive Officer, Mainolfi Nello completed a deal on Dec 08 ’25 to sell 100000.0 shares. Meanwhile, Chief Medical Officer Gollob Jared sold 49307.0 shares on Dec 08 ’25.
